List of Excipients in Branded Drug SYPRINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	SYPRINE	trientine hydrochloride	0187-2120	GELATIN
Bausch Health US LLC	SYPRINE	trientine hydrochloride	0187-2120	STEARIC ACID
Bausch Health US LLC	SYPRINE	trientine hydrochloride	0187-2120	TITANIUM DIOXIDE

SYPRINE Excipient Strategy and Commercial Opportunities in Wilson Disease

Last updated: September 24, 2026

SYPRINE is a trientine hydrochloride capsule approved for the treatment of Wilson disease in patients who are intolerant of penicillamine. The commercial opportunity is concentrated in improved oral delivery, pediatric administration, food-interaction management, generic substitution, and differentiated trientine formulations. The incumbent product has a relatively simple solid-dose design, leaving room for products that improve adherence, dosing flexibility, storage, and administration without changing the active ingredient.

What is SYPRINE and which excipients does it contain?

SYPRINE contains trientine hydrochloride in 25 mg and 75 mg capsules. The product is administered orally and is labeled for Wilson disease patients who cannot tolerate penicillamine. The labeled dose is generally divided into two, three, or four daily administrations, creating an adherence burden for chronic treatment.[1]

The SYPRINE formulation uses a conventional hard-gelatin capsule platform. Public labeling identifies inactive ingredients that include lactose monohydrate, crospovidone, magnesium stearate, and colloidal silicon dioxide. The capsule shell contains standard gelatin-based components and colorants.[1,2]

Product attribute	SYPRINE
Active ingredient	Trientine hydrochloride
Dosage forms	25 mg and 75 mg capsules
Indication	Wilson disease in patients intolerant of penicillamine
Route	Oral
Administration issue	Food and mineral products can reduce trientine exposure
Typical use	Chronic maintenance therapy
Key formulation constraint	Dose separation from food and certain mineral supplements
Primary commercial owner	Bausch Health through its specialty pharmaceutical portfolio

The excipient system is not the main differentiator of SYPRINE. Its commercial performance depends more heavily on the active ingredient's administration restrictions, chronic dosing schedule, limited patient population, and specialist prescribing base.

What excipient strategy is most relevant for SYPRINE?

The strongest excipient strategy is to improve reproducibility, administration convenience, and patient acceptability while preserving the fasting-use profile required for trientine.

Improve capsule fill uniformity

Trientine hydrochloride products require consistent low-dose and high-dose capsule fills. A formulation developer could optimize:

• Particle-size distribution of the active ingredient
• Carrier selection
• Flow-enhancing silica levels
• Lubricant concentration
• Granulation versus direct-compression processing
• Blend segregation control
• Capsule weight variation

A more robust blend could reduce manufacturing variability and support lower-cost generic production. The commercial value is highest if the formulation reduces batch failures, improves content uniformity, or permits smaller capsule sizes.

Reduce capsule burden

SYPRINE requires multiple daily doses. A 75 mg capsule reduces the number of units needed, but some patients require mixed 25 mg and 75 mg dosing. Opportunities include:

• Higher-strength capsules
• Combination-strength packaging
• Scoreable or divisible tablets
• Multiparticulate sachets
• Sprinkle formulations for patients with swallowing limitations

Any higher-strength product would need to address dose flexibility. A large capsule can reduce adherence if it is difficult to swallow, particularly in pediatric patients.

Develop pediatric-friendly dosage forms

Wilson disease can present in children and adolescents. A liquid, dispersible tablet, oral powder, or granule product could address patients who cannot swallow capsules. The excipient platform would need to control:

• Taste and metallic or bitter flavor
• Chemical stability in water or suspensions
• Microbial preservation
• Sedimentation and redispersibility
• Dose uniformity after storage
• Compatibility with enteral feeding devices

A pediatric product could command a premium if it offers reliable dosing for young patients without requiring caregivers to manipulate capsules.

Control moisture and chemical stability

Trientine products require packaging and formulation controls that limit moisture exposure and preserve potency over shelf life. Relevant technologies include:

• High-barrier blister packaging
• Desiccant-containing bottles
• Low-moisture excipient systems
• Nitrogen-flushed packaging
• Unit-dose packaging
• Moisture-resistant capsule shells

Packaging can be commercially important even when the formulation is unchanged. A company could obtain meaningful differentiation through stability data, child-resistant unit-dose systems, and improved portability.

How do food and mineral interactions affect excipient design?

Trientine absorption is affected by food. The SYPRINE label instructs patients to take the product on an empty stomach, generally at least one hour before or two hours after food.[1] Iron, zinc, calcium, and other mineral products can also interfere with therapy and may require separation from trientine administration.

This constraint limits the value of conventional strategies intended to increase oral absorption. A formulation that increases exposure in the fed state could have greater commercial value than one that merely improves powder flow.

Potential approaches include:

1. Food-tolerant formulations. Lipid-based or polymeric systems could attempt to reduce food-related variability, although the active ingredient's chelation chemistry and absorption mechanism would make this technically challenging.

2. Modified-release systems. Delayed or extended release could reduce dosing frequency, but release timing would need to avoid the postprandial period and preserve clinically adequate exposure.

3. Mineral-resistant delivery. A formulation could attempt to limit interaction with gastrointestinal minerals through enteric protection, controlled release, or molecular complexation.

4. Administration aids. Packaging and labeling could provide dose-timing tools, calendar packs, and separate compartments for trientine and mineral supplements.

The strongest near-term opportunity is usually administration support rather than a technically complex absorption enhancer. Any product that changes exposure would require comparative pharmacokinetic and clinical justification.

What formulations are protected or commercially differentiated in the trientine market?

The main formulation categories are capsules, tablets, and potential pediatric liquid or multiparticulate products.

Formulation	Commercial advantage	Main technical risk	Likely regulatory pathway
Conventional capsule	Low development cost; direct generic competition	Limited differentiation	ANDA if bioequivalence can be established
High-strength capsule	Fewer daily units	Reduced dosing flexibility; larger capsule size	ANDA or 505(b)(2), depending on changes
Immediate-release tablet	Potentially easier swallowing and manufacturing	New excipient and dissolution profile	ANDA or 505(b)(2)
Dispersible tablet	Pediatric and dysphagia use	Taste, dispersion, dose uniformity	505(b)(2) or new drug application
Oral liquid	Flexible pediatric dosing	Stability, preservation, taste, packaging	505(b)(2) or new drug application
Modified-release product	Potential dosing reduction	Food effect and exposure risk	505(b)(2) or new drug application
Unit-dose blister	Better adherence and moisture control	Packaging cost	Product or packaging differentiation

SYPRINE's conventional capsule design leaves the largest white space in pediatric delivery, unit-dose packaging, and lower-burden dosing. A reformulated product would need to demonstrate a practical benefit that justifies development and regulatory costs in a small orphan-disease market.

When does SYPRINE lose exclusivity?

SYPRINE's market protection is not determined by one date. It depends on patents, FDA regulatory exclusivity, orphan-drug provisions, and the timing of approved generic or alternative trientine products.

The product has long been commercially available, and the relevant market has already moved beyond a pure branded-monopoly model. Trientine products from other manufacturers have entered or approached the U.S. market, while CUVRIOR, a trientine tetrahydrochloride tablet, was approved by FDA in 2022 for Wilson disease.[3]

The practical exclusivity analysis is therefore:

• Active-ingredient exclusivity: expired or commercially ineffective because trientine is an established active ingredient.
• Orphan exclusivity: historically important, but the timing depends on the specific product and indication.
• Formulation patents: potentially relevant to specific dosage forms, strengths, manufacturing processes, or delivery technologies.
• Orange Book status: must be assessed for current listed patents and regulatory exclusivity associated with each approved product.
• Generic entry: depends on whether an ANDA applicant can establish pharmaceutical equivalence and bioequivalence or must use a more burdensome 505(b)(2) pathway.

A new formulation should not rely on broad claims to trientine alone. Commercially defensible claims are more likely to cover a specific composition, release profile, pediatric dosage form, packaging configuration, stability improvement, or administration method.

What is the FDA regulatory status of SYPRINE and competing trientine products?

SYPRINE is FDA-approved as an oral trientine hydrochloride capsule. CUVRIOR is an FDA-approved trientine tetrahydrochloride tablet developed by Orphalan for Wilson disease.[3]

The different salt forms create both opportunities and limits. A new salt or dosage form may avoid direct pharmaceutical-equivalence treatment if it is not therapeutically equivalent to the reference product. It may instead require a 505(b)(2) application supported by clinical or pharmacokinetic bridging.

Regulatory comparison

Regulatory issue	SYPRINE capsule	CUVRIOR tablet	New pediatric or modified-release product
Active moiety	Trientine	Trientine	Trientine
Salt/form	Hydrochloride	Tetrahydrochloride	May vary
FDA pathway	Approved product	Approved product	Likely ANDA, 505(b)(2), or NDA
Main approval challenge	Maintaining quality and supply	Demonstrating tablet performance and safety	Bridging exposure, dose, and administration
Differentiation	Established capsule	Tablet platform	Pediatric, adherence, stability, or dosing benefit

The route matters commercially. A conventional trientine hydrochloride capsule may be suitable for an ANDA. A new salt, pediatric liquid, or controlled-release product may require a 505(b)(2) application and potentially more extensive clinical support.

Which companies are challenging or competing with SYPRINE?

Competition includes generic manufacturers, specialty orphan-drug companies, and developers of alternative trientine salts or dosage forms.

Bausch Health

Bausch Health is associated with SYPRINE and has historically marketed trientine hydrochloride capsules in the United States. Its commercial advantages include brand recognition, prescriber familiarity, and an established product history. Its vulnerabilities include price competition, supply expectations, and limited formulation differentiation.

Orphalan

Orphalan developed CUVRIOR, a tablet-based trientine product. The tablet platform creates a direct commercial alternative to capsule-based SYPRINE and can support differentiated branding, dosing instructions, and patient-support programs.[3]

Generic manufacturers

Generic companies can compete through:

• Trientine hydrochloride capsules
• Lower-cost supply contracts
• Pharmacy substitution
• Specialty-distributor access
• Alternative packaging
• Authorized-generic arrangements

The generic opportunity is constrained by the small Wilson disease population and the need for reliable specialty distribution. A low-cost entrant may achieve modest volume but still face limited absolute revenue because the patient population is rare.

What patent litigation and Paragraph IV risks affect SYPRINE?

Paragraph IV risk depends on the patents listed for the relevant reference product at the time of an ANDA filing. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. The patent holder can file suit within 45 days, potentially triggering a 30-month stay under the Hatch-Waxman framework.[4]

For SYPRINE, the highest-value patent targets would generally be:

• Composition-of-matter claims, if any remain enforceable
• Specific capsule compositions
• Stability-enhancing excipient combinations
• Particle-size or manufacturing-process claims
• Dosing methods involving food or mineral separation
• Pediatric dosage forms
• Salt-form or polymorph claims
• Packaging claims tied to moisture stability

Method-of-use claims may be difficult to enforce where the labeled administration instructions are already known and routinely followed. Formulation and manufacturing claims may offer stronger commercial leverage if they cover a product characteristic that a generic cannot easily avoid.

A product developer should map U.S. patents in the Orange Book, FDA patent certifications, USPTO prosecution records, and any district-court litigation before selecting a salt or dosage form. No single patent category should be treated as sufficient protection.

How strong is the SYPRINE patent estate?

The commercial strength of SYPRINE's estate is likely weaker than that of a recently launched small-molecule product because trientine is an old active ingredient and the core capsule concept is conventional. The strongest protection would come from narrow, enforceable formulation or manufacturing claims rather than broad claims covering trientine treatment.

Patent category	Expected strength for a conventional trientine capsule	Strategic assessment
Active ingredient	Low	Established compound
Basic capsule composition	Low to moderate	Vulnerable to design-around
Specific excipient combination	Moderate	Useful if linked to stability or bioequivalence
Pediatric liquid	Moderate to high	Stronger if taste, stability, and dosing claims are supported
Modified release	Moderate	Technically difficult but potentially differentiated
Manufacturing process	Moderate	Valuable if process is difficult to replicate
Packaging and moisture control	Low to moderate	More useful as supporting protection
Method of administration	Low to moderate	Enforcement may be difficult

The best defensible strategy is a layered estate covering composition, process, stability, packaging, and patient-specific administration. Patent claims should be supported by comparative data, not only routine formulation descriptions.

What commercial opportunities exist beyond SYPRINE?

Generic capsule supply

A conventional generic can compete on price and contracting. The opportunity is most attractive for a manufacturer with existing specialty-pharmacy infrastructure and low-cost capsule manufacturing. Volume is limited, but the product may fit a broader orphan-drug portfolio.

Pediatric trientine

A ready-to-use oral liquid or dispersible product could address a clear administration gap. Commercial advantages include:

• Weight-based dosing
• Easier administration for children
• Reduced capsule swallowing burden
• Potential use in patients with dysphagia
• Improved caregiver control

Taste masking is likely to be a central development issue. Sweeteners, flavors, viscosity modifiers, and preservatives must be selected without compromising chemical stability or dose uniformity.

Adherence and dosing systems

Calendar packaging, unit-dose blisters, and digital adherence tools can support chronic therapy. These products may be attractive to specialty pharmacies and payers if they reduce missed doses or prevent administration errors involving food and minerals.

International licensing

Trientine is commercialized in multiple jurisdictions under different salts and brands, including Cuprior in Europe. A company with a differentiated formulation could license regional rights to specialty pharmaceutical firms that already sell rare-disease products. The most licensable assets would be a pediatric formulation, a stable liquid, or a product with evidence supporting less restrictive administration.

Manufacturing and supply contracts

Manufacturing reliability is commercially relevant because Wilson disease patients require continuous treatment. Opportunities include:

• Dual-source supply
• Domestic or regional manufacture
• High-barrier packaging
• Finished-dose contract manufacturing
• Specialty-pharmacy distribution
• Emergency replacement programs

A supplier that can guarantee capsule availability and stable lead times may win contracts even without a novel excipient system.

What revenue exposure does SYPRINE represent?

Wilson disease is a rare disorder, so the addressable patient population is small relative to mass-market pharmaceuticals. Revenue depends on product price, diagnosis rates, persistence, payer coverage, and competition from generic capsules and branded tablets.

A simple market model is:

Variable	Commercial effect
Diagnosed U.S. patients	Limits total unit demand
Chronic treatment duration	Supports recurring revenue
Multiple daily doses	Increases annual capsule consumption
Generic substitution	Reduces branded price and share
Specialty distribution	Raises operational requirements
Pediatric share	Increases value of liquid or dispersible products
Reimbursement	Determines realized net price
Supply reliability	Influences prescriber and pharmacy preference

The most attractive commercial strategy is unlikely to be a broad mass-market launch. It is a focused specialty product with a clear administration or adherence advantage, supported by orphan-disease distribution and reimbursement expertise.

Key Takeaways

• SYPRINE is a trientine hydrochloride capsule available in 25 mg and 75 mg strengths.
• The main formulation opportunity is not a routine excipient substitution. It is improved pediatric delivery, moisture stability, dosing convenience, or food-interaction management.
• A liquid, dispersible tablet, or multiparticulate product could address the largest patient-use limitations.
• Conventional generic capsules face limited technical barriers but operate in a small specialty market.
• CUVRIOR provides a direct branded tablet competitor and demonstrates commercial interest in alternative trientine dosage forms.
• Patent value is likely to reside in formulation, process, stability, and pediatric-use claims rather than broad trientine claims.
• The most credible licensing targets are differentiated pediatric and adherence products.
• Commercial success will depend on regulatory pathway, specialty distribution, reimbursement, and supply reliability as much as on excipient selection.

FAQs

Can SYPRINE be reformulated as an oral liquid?

Yes. An oral liquid is technically plausible, but development would need to address trientine stability, taste, preservation, sedimentation, dose uniformity, and packaging. A 505(b)(2) pathway may be appropriate if the product differs materially from the approved capsule.

Would a higher-strength SYPRINE capsule improve adherence?

It could reduce capsule count, but a larger capsule may worsen swallowing difficulty and reduce dose flexibility. The commercial value would depend on whether the higher strength matches common maintenance doses.

Can excipients eliminate SYPRINE's fasting requirement?

No conventional excipient change can be assumed to eliminate the fasting requirement. A developer would need pharmacokinetic and clinical evidence showing that the reformulated product provides consistent exposure with food.

Is a trientine tablet a generic equivalent to SYPRINE?

Not necessarily. A tablet containing a different trientine salt or formulation may require a 505(b)(2) application rather than an ANDA, depending on pharmaceutical equivalence and FDA classification.

What is the most valuable new product opportunity in the SYPRINE market?

A stable, taste-masked pediatric formulation with flexible dosing is likely the most differentiated opportunity. A lower-cost capsule can compete on price, but a pediatric product can address a defined clinical and administration need.

References

1. U.S. Food and Drug Administration. (n.d.). SYPRINE (trientine hydrochloride) capsule: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: SYPRINE- trientine hydrochloride capsule.
3. U.S. Food and Drug Administration. (2022). CUVRIOR (trientine tetrahydrochloride) tablets: Prescribing information.
4. U.S. Food and Drug Administration. (2017). Applications covered by section 505(b)(2). FDA Guidance for Industry.